



The Statistics and Pharmacometrics Interest Group (SxP): Membership and Mission

Fred Balch, Alan Hartford, Matthew Rotelli, Bret Musser, Enrico Smith, Brian Smith, Stacey Tannenbaum, Jose' Pinheiro, France Mentre

SxP: About the Group


The Statistics and Pharmacometrics Interest Group (SxP) was named in 2016 and is chartered by both the American Statistical Association (ASA) and the International Society of Pharmacometrics (ISOP). The current steering committee is by design an eclectic and international mixture of scientists from statistical and pharmacometrics backgrounds with a shared vision of excellence in pharmaceutical research

- 222 Members based on free signup.
- Responder Analysis:
 - Employer
 - 54% Big Pharma
 - 24% Academic
 - 19% Consultants
 - Discipline (Many responded to more than 1).
 - 72% Pharmacometrician
 - 60% Statistician
 - 23% Pharmacokineticist

SxP: Goals

- SxP promotes collaboration between Statisticians and Pharmacometricians, to enable each discipline to learn and grow from interactions with each other and to develop innovative approaches to model informed drug development.
- The goals of the interest group are to:**
 - Provide educational opportunities to learn about Statistics and Pharmacometrics
 - Encourage career growth and mentoring for people new in the field
 - Promote cross-disciplinary methodology research and publications, and to encourage cross participation at conferences
 - Create best practices leveraging both disciplines
 - Provide opportunities to discuss computing platforms and share code


According to our survey, NONMEM remains the most widely used software package for pharmacometric modeling followed by R



Survey: Open Ended Responses

#	RESPONSES	DATE
1	Develop and deliver curricula for cross-training Stats for PMx and PMx for Stats. Publish papers on practical resolutions to common issues.	10/21/2017 9:06 AM
2	Collect money and use it to organise training and dissemination of good practices.	10/19/2017 4:13 AM
3	Create opportunities for greater interactions and better understanding between pharmacometricians and statisticians	10/12/2017 7:51 AM
4	What is PDUFA6?	10/5/2017 1:01 PM
5	Organizing sessions in both stat and PHM conferences, working groups to publish tutorials/white papers...	9/19/2017 3:32 AM
6	By making data-based decisions a common occurrence via efficient interaction between PMx, Stats, Commercial, etc...	9/18/2017 1:40 PM
7	More interaction with ASA Biopharm section. More discussions on methodology with everyone.	9/15/2017 1:00 PM
8	Help with the translation of the two "languages". Find common ground (like R?). MCP-Mod training for both groups, geared towards the specific discipline's understanding and needs. Joint programming and publications- bring people together to work on these. Buddy system (pair up a stat and PMx who want to learn more from each other).	9/15/2017 12:26 PM
9	Quarterly meetings to be held virtually for members - that include a "guest speaker" as well as "round the mic" discussions.	9/15/2017 8:05 AM
10	There are (still) many areas where P could learn from S and vice-versa. In my experience, Working Group on key topics and delivering white papers, for instance, have been effective ways to address key questions. So, I would think that if SxP could focus on 2-5 key questions and work on these in sub teams, that could be useful to the broad SxP community. Hope that help (and thank you for organizing this!)	9/15/2017 3:11 AM
11	Sessions at ACoP, discussion boards online, and tutorials in journals or online can help the rest of us learn more statistics. In all of these, defining even the most basic of terms is helpful for those of us with different backgrounds.	9/14/2017 7:43 PM
12	Provide more tutorial type of training.	9/14/2017 5:11 PM
13	SxP should aim for genuine debate on contentious issues, and ought not shy away from confronting possibly serious errors committed by "both sides". Also, we must appreciate that we are not serving "the profession" (which one?) but rather THE PATIENT.	9/14/2017 3:55 PM



SxP: Website
<http://community.amstat.org/sxp/home>



Link to ISOP Website:
<http://discuss.go-isop.org/c/pharmacometrics-with-asa-pasa>

SxP Recent Presentations to ASA, ISOP		
Meeting	Title	Presenter(s)
2017 Joint Statistical Meetings	Pharmacometric Programming	Amit Roy, Jing Su, Neelima Thanneer, and Jeffrey Florian, Brett Musser
2017 ASCPT	Bridging the Gap Between Pharmacometricians and Statisticians in Clinical Pharmacology and Therapeutics	France Mentre
2016 FDA-Industry Workshop	Moving Pharmacometrics and Statistics Beyond a Marriage of Convenience - Improving Discipline Synergy and Drug Development Decision Making	Misook Park, Dionne L. Price, Matthew David Rotelli, Alfred H. Balch, Jeffrey Barrett, Sanofi, Jeffrey Florian, France Mentre

Our survey shows you can find our members at many pharmacometrics and statistics meetings, with strongest attendance at ACOP and PAGE



For additional information please contact:
Alfred Balch, SxP Outreach
Division of Clinical Pharmacology
University of Utah
Alfred.Balch@hsc.utah.edu

Draft Charter for the Education/Best Practices/Technical Issues Subteam of SxP 2017			
Purpose/Objective	Scope	High Level Project Plan	
<ol style="list-style-type: none"> Increase awareness among pharmacometricians and statisticians on similarities and commonalities between the two disciplines, when approaching quantitative problems. Promote educational and best practices activities and initiatives to foster complementary collaboration and mutual understanding between pharmacometricians and statisticians. 	<ol style="list-style-type: none"> Identification of opportunities for further collaboration between pharmacometricians and statisticians, and shared learning needs/interests. Define educational/best practices activities based on identified collaboration and learning opportunities. Initiate activities in the collaboration nexus between pharmacometrics and statistics, evaluating their effectiveness and impact. 	Milestones	Timelines
		<ul style="list-style-type: none"> Survey of SxP membership Analyze and summarize results from initial survey Survey of ASA BIOP and ISoP memberships Analyze and summarize results from second round of surveys Consider publishing key findings from survey, with recommendations on both statistical (e.g., Statistical in Biopharmaceutical Research) and Clinical Pharmacology journals (e.g., CPT) Devise and implement educational and best practices priorities and activities: e.g., webinars, short courses, self-learning literature database, commentaries on guidance documents, etc. Ensure continuity of SxP influence on/involvement in ISoP and ASA BIOP Section, by encouraging/nominating SxP members to run for office in the societies. 	<ul style="list-style-type: none"> Pharmaceutical companies Pharmaceutical regulators Academia
Committee Members	Rob Bies, Kevin Dykstra, Jonathan French, Lena Friberg, Alan Hartford, France Mentre, Jose Pinheiro, Dionne Price, Yaning Wang	Risks/Resources	
Advisors			